Cetrelimab — Drug Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

1 Recruiting

8 Completed trials

3 Sponsors

12 Countries

Phase III

Phase II

Phase I/II

Phase I (FiH)

Phase III: 2 Phase II: 3 Phase I/II: 3 Phase I (FiH): 1

Indications tested

Bladder cancer 1

Sponsors using this IMP

Janssen - Cilag International 7 Grupo Espanol De Oncologia Genitourinaria-Socug 1 Universitair Medisch Centrum Groningen 1

All trials

9 total

CD8 PET imaging in metastatic solid tumours; A phase II, open label, multi-center study of 89Zr-DF-crefmirlimab for CD8 positron emission to… Recruiting

2024-515885-15-00 Phase I/II 2 countries Universitair Medisch Centrum Groningen
Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Part… Ended

2023-506146-23-00 Phase II 8 countries Janssen - Cilag International
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer (PolyDamas) Ended

2022-501452-29-00 Phase I/II 3 countries Janssen - Cilag International
A Phase 2, open-label, multi-centre, multi-national interventional trial to evaluate the efficacy and safety of erdafitinib (ERDA) monothera… Ended

2024-512573-27-01 Phase II 3 countries Grupo Espanol De Oncologia Genitourinaria-Socug
Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 … Ended

2023-507187-39-00 Phase III 9 countries Janssen - Cilag International
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (M… Ended

2023-507188-21-00 Phase III 10 countries Janssen - Cilag International
A study to evaluate the safety, the distribution and elimination of the compound in the body, and the effectiveness of Erdafitinib by itself… Ended

2023-510295-31-00 Phase I/II 1 country Janssen Cilag International
A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723… Ended

2023-506144-16-00 Phase I (FiH) 2 countries Janssen - Cilag International
A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Mu… Ended

2023-507189-17-00 Phase II 6 countries Janssen - Cilag International

Showing 1–9 of 9 trials

← All drugs A–Z